Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05334732 | Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)(SIS) | active not recruiting | N/A | 225 | Virginia Commonwealth UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05767424 | Prospective Observational Study for Breast Microcalcifications' Classification With Artificial Intelligence Techniques | active not recruiting | — | 1,426 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT05798338 | Characterization of Extracellular Vesicles in Breast Cancer Patients | recruiting | — | 105 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05942105 | Different Localization Techniques for Non-palpable Breast Lesions Comparison: a Retrospective and Multicentric Clinical Study(Localization01) | active not recruiting | — | 1,064 | Istituti Clinici Scientifici Maugeri SpAOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06123988 | Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer(FastER) | recruiting | N/A | 260 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06533826 | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd(TRADE DXd) | recruiting | Phase 2 | 357 | Ana C Garrido-Castro, MDOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06577987 | Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | active not recruiting | Phase 1 | 220 | Circle PharmaINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06891833 | A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer | recruiting | Phase 2 / Phase 3 | 985 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07109817 | Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer(DETOXp) | recruiting | Phase 2 | 116 | Montefiore Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07222215 | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)(CAPELA) | recruiting | Phase 2 | 297 | Kristina A. FanucciOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07227831 | A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer | recruiting | N/A | 82 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07383506 | A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 90 | Cogent Biosciences, Inc.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07782840 | QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07784660 | Molecular Imaging of EpCam Expression in Breast Cancer Using [99mTc]Tc-DARPinEc1-G3C(EpCam-Scan) | enrolling by invitation | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC(DETENTE-1) | not yet recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787338 | SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | not yet recruiting | Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | not yet recruiting | Phase 2 | 48 | Yonsei UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT00899301 | Collecting and Storing Tissue Samples From Women With or Without Breast Cancer | recruiting | — | 4,000 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT01327781 | Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05483491 | KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer | recruiting | Phase 1 | 30 | Christian HinrichsOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06067503 | Biomarkers to Detect Endocrine Therapy Resistance | recruiting | Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06545682 | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | recruiting | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06856343 | REBECCA Real-world Early BrEast CanCer mAnagement(REBECCA) | recruiting | — | 126 | AstraZenecaINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | active not recruiting | Phase 1 | 21 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07669467 | Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer(NuvastaticTM) | recruiting | Phase 3 | 250 | Natureceuticals Sdn BhdINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784036 | JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer | not yet recruiting | Phase 3 | 171 | Chengdu JOYO pharma Co., Ltd.INDUSTRY | 0 | Aug 25, 2026 | clinicaltrials |
| NCT07786051 | DiEtary Mimicry by Glucocorticoid Modulation Evaluation in ER+ Metastatic Breast Cancer Treatment: Efficacy and Response (DEMETER Trial)(DEMETER) | not yet recruiting | Phase 2 | 80 | The Netherlands Cancer InstituteOTHER | 0 | Aug 25, 2026 | clinicaltrials |
| NCT05035836 | A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05501704 | ETHAN - ET for Male BC | recruiting | Phase 2 | 60 | Jose Pablo LeoneOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.(ADELA) | recruiting | Phase 3 | 300 | MedSIROTHER | 9 | Aug 24, 2026 | clinicaltrials |
| NCT06590857 | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.(TRACY-1) | active not recruiting | Phase 1 / Phase 2 | 16 | RayzeBio, Inc.INDUSTRY | 3 | Aug 24, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07659652 | Quality of Life for Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease | not yet recruiting | — | 200 | University of California, San FranciscoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)(NeoTILs) | recruiting | Phase 2 | 55 | Medical University of South CarolinaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07780955 | Multimodal Assessment of Cryotherapy for Paclitaxel-Induced Neuropathy | recruiting | N/A | 144 | Azienda Sanitaria dell'Alto AdigeOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781163 | Evaluation of the Safety and Efficacy of Single-Port Robot-Assisted Endoscopic Breast-Conserving Surgery and Nipple-sparing Matectomy With Reconstruction in Early-Stage Breast Cancer Patients | not yet recruiting | N/A | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07781306 | PrOspEctive Metastases Imaging (POEM)(POEM) | recruiting | — | 50 | Cancer Research AntwerpOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07782086 | A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer(Veri-HER2UL) | not yet recruiting | N/A | 30 | Shuangyue LiuOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07782866 | MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors | completed | N/A | 46 | The Healing Consciousness FoundationOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05593094 | A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 210 | Hoffmann-La RocheINDUSTRY | 7 | Aug 21, 2026 | clinicaltrials |
| NCT06384417 | Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 | completed | N/A | 30 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06441890 | BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer(BRE-10) | recruiting | Phase 2 | 28 | University of Illinois at ChicagoOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06536881 | Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming(GAMMER) | recruiting | N/A | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 21, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 26, 2026source: clinicaltrials